METTL3 and hepatocellular carcinoma: demonstrated that METTL3 significantly reduces the infiltration of granzyme B (GZMB+) and interferon-gamma-positive (IFN-γ+) CD8+ T cells during the development of liver cancer, thereby inhibiting tumor immunity and promoting immune evasion in HCC.